Marinomed Biotech Management
Management criteria checks 2/4
Marinomed Biotech's CEO is Andreas Grassauer, appointed in Apr 2006, has a tenure of 18.17 years. total yearly compensation is €307.20K, comprised of 72.3% salary and 27.7% bonuses, including company stock and options. directly owns 7.9% of the company’s shares, worth €1.53M. The average tenure of the management team and the board of directors is 18.2 years and 2 years respectively.
Key information
Andreas Grassauer
Chief executive officer
€307.2k
Total compensation
| CEO salary percentage | 72.3% |
| CEO tenure | 18.2yrs |
| CEO ownership | 7.9% |
| Management average tenure | 18.2yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -€7m |
| Dec 31 2023 | n/a | n/a | -€7m |
| Sep 30 2023 | n/a | n/a | -€6m |
| Jun 30 2023 | n/a | n/a | -€6m |
| Mar 31 2023 | n/a | n/a | -€7m |
| Dec 31 2022 | €307k | €222k | -€6m |
| Sep 30 2022 | n/a | n/a | -€5m |
| Jun 30 2022 | n/a | n/a | -€5m |
| Mar 31 2022 | n/a | n/a | -€6m |
| Dec 31 2021 | €300k | €200k | -€6m |
| Sep 30 2021 | n/a | n/a | -€8m |
| Jun 30 2021 | n/a | n/a | -€7m |
| Mar 31 2021 | n/a | n/a | -€7m |
| Dec 31 2020 | €324k | €200k | -€6m |
| Sep 30 2020 | n/a | n/a | -€6m |
| Jun 30 2020 | n/a | n/a | -€6m |
| Mar 31 2020 | n/a | n/a | -€6m |
| Dec 31 2019 | €440k | €200k | -€7m |
| Sep 30 2019 | n/a | n/a | -€14m |
| Jun 30 2019 | n/a | n/a | -€15m |
| Mar 31 2019 | n/a | n/a | -€14m |
| Dec 31 2018 | €177k | €177k | -€12m |
Compensation vs Market: Andreas's total compensation ($USD329.90K) is about average for companies of similar size in the UK market ($USD357.94K).
Compensation vs Earnings: Andreas's compensation has increased whilst the company is unprofitable.
CEO
Andreas Grassauer (55 yo)
18.2yrs
Tenure
€307,200
Compensation
Mr. Andreas Grassauer, PhD, is a Co-Founder of Marinomed Biotechnology GmbH in 2006 and serves as its Chairman of Management Board and has been Chief Executive Officer since 2006. Mr. Grassauer has co-foun...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 18.2yrs | €307.20k | 7.9% € 1.5m | |
| Co-Founder | 18.4yrs | €299.60k | 7.9% € 1.5m | |
| CFO & Member of Management Board | 5.8yrs | €311.70k | no data | |
| Head of Investor Relations | no data | no data | no data |
18.2yrs
Average Tenure
55yo
Average Age
Experienced Management: MARIV's management team is seasoned and experienced (18.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of Supervisory Board | 7yrs | €65.30k | no data | |
| Independent Vice Chairwoman of the Supervisory Board | 5.6yrs | €20.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Member of Supervisory Board | 2yrs | €7.50k | no data | |
| Independent Member of Supervisory Board | 2yrs | €10.00k | no data | |
| Member of Supervisory Board | 1yr | no data | no data |
2.0yrs
Average Tenure
59yo
Average Age
Experienced Board: MARIV's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/25 04:51 |
| End of Day Share Price | 2024/03/28 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marinomed Biotech AG is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Norbert Kalliwoda | Dr. Kalliwoda Research |
| Vladimira Urbankova | Erste Group Bank AG |
| Christian Ehmann | FMR - Frankfurt Main Research AG |